Extract of bacteria of the genus Sphingomonas

The Sphingomonas extract addresses the limitations of existing treatments by activating hTLR2 receptors, inhibiting PGE2 secretion, and modulating interleukins, effectively reducing inflammation and strengthening the skin barrier to treat allergic skin reactions.

FR3117777B1Active Publication Date: 2024-11-29LOREAL SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
FR2021009095
Authority / Receiving Office
FR · FR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-12-18
Filing Date
2021-08-31
Publication Date
2024-11-29
Estimated Expiration
2041-08-31

AI Technical Summary

Technical Problem

Existing treatments for skin reactions caused by allergic reactions are inadequate in modulating immune responses and strengthening the skin's barrier function, leading to ineffective prevention and treatment of symptoms such as hives and redness.

Method used

An extract from the Sphingomonas genus of bacteria is used to activate hTLR2 receptors, promote expression of genes linked to skin barrier strengthening, inhibit pro-inflammatory mediator PGE2 secretion, and modulate interleukin expression, thereby reducing IgE production and inflammation.

Benefits of technology

The Sphingomonas extract effectively reduces skin inflammation, strengthens the skin barrier, and modulates immune responses, providing significant relief from allergic skin reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000025_0000
    Figure 00000025_0000
  • Figure 00000025_0001
    Figure 00000025_0001
  • Figure 00000025_0002
    Figure 00000025_0002
Patent Text Reader

Abstract

Extract of bacteria of the genus Sphingomonas. The present invention relates to an extract of bacteria of the genus Sphingomonas, and to compositions comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas, for their use in the prevention and / or treatment of skin reactions caused by an allergic reaction and for their use in modulating the immune response and optionally in strengthening the skin barrier function. Figure for the abstract: none
Need to check novelty before this filing date? Find Prior Art

Description

Title of the invention: Extract of bacteria of the genus Sphingomonas

[0001] The present invention relates to an extract of bacteria of the genus Sphingomonas, and compositions comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas for their use in the prevention and / or treatment of skin reactions caused by an allergic reaction and for their use in the modulation of the immune response and optionally in strengthening the skin barrier function.

[0002] Allergy is a complex phenomenon in which an exaggerated inflammatory reaction occurs following exposure of the body to an allergen. Allergy depends in particular on two factors: the permeability of the barrier between the body and the external environment, and the regulation of the immune system.

[0003] Thus, allergy depends on skin permeability, which acts as a barrier against external aggressions, particularly particulate, chemical, or mechanical, but also to limit the loss of water and other interstitial compounds. This property of the skin is called the barrier function. The barrier function is ensured in particular by tight junctions and associated proteins. By stimulating the expression of these proteins and the formation of tight junctions, the activation of Toll-like receptor 2 (TLR2) strengthens the barrier function.

[0004] Allergy also depends on the regulation of the immune system, in particular via type E antibodies (IgE), prostaglandin E2 (PGE2) and various interleukins (IL).

[0005] IgE participates in the immediate type allergic reaction which can cause urticaria or Quincke's edema.

[0006] PGE2 and IL-6 / IL-8 also play a role in attracting neutrophils. They exhibit a complementary mode of action: on the one hand, through an increase in vascular permeability for PGE2, and on the other hand, through a chemokine gradient that attracts neutrophils for IL-6 or IL-8. These two different and combined modes of action thus improve the inflammatory response.

[0007] The inventors discovered that an extract of Sphingomonas activates hTLR2 receptors in vitro and promotes the expression of genes related to strengthening the skin barrier function. They also showed that this extract inhibits the secretion of the pro-inflammatory mediator PGE2 and modulates the expression of interleukins promoting IL-10 (an anti-inflammatory cytokine) without significantly impacting other pro-inflammatory interleukins such as IL-12, IL-6, and IL-8. Finally, the inventors showed that the extract limits the production of IgE by human B lymphocytes.

[0008] Thus, bacteria of the genus Sphingomonas and their extracts have several activities anti-inflammatory properties combined with strengthening of the skin's barrier function, allowing the prevention and / or treatment of skin reactions caused by an allergic reaction.

[0009] The present invention thus relates to an extract of bacteria of the genus Sphingomonas for its use in the prevention and / or treatment of skin reactions caused by an allergic reaction.

[0010] The present invention also relates to a composition comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas for its use in the prevention and / or treatment of skin reactions caused by an allergic reaction.

[0011] The present invention also relates to an extract of bacteria of the genus Sphingomonas for its use in modulating the immune response and optionally in strengthening the skin barrier function.

[0012] Furthermore, the present invention relates to a composition comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas, for its use in the modulation of the immune response and optionally the strengthening of the skin barrier function. Detailed description of the invention

[0013] General definitions

[0014] The term “bacteria” refers to a prokaryotic microorganism, preferably a pro-teobacterium, in a living, semi-active, inactivated or dead form.

[0015] The bacterium used according to the invention or the bacterium of the extract used according to the invention is of the genus Sphingomonas.Dans un mode de réalisation, la bactérie est d’une espèce choisie parmi Sphingomonas abaci, Sphingomonas adhaesiva, Sphingomonas aerolata, Sphingomonas aquatilis, Sphingomonas asaccharolytica, Sphingomonas aurantiaca, Sphingomonas azotifigens, Sphingomonas dokdonensis, Sphingomonas echinoides, Sphingomonas faeni, Sphingomonas fennica, Sphingomonas haloaromaticamans, Sphingomonas jaspsi, Sphingomonas koreensis, Sphingomonas mali, Sphingomonas melonis, Sphingomonas natatoria, Sphingomonas oligophenolica, Sphingomonas panni, Sphingomonas parapaucimobilis, Sphingomonas paucimobilis, Sphingomonas phyllosphaerae, Sphingomonas pituitosa, Sphingomonas pruni, Sphingomonas roseiflava, Sphingomonas sanguinis, Sphingomonas soli, Sphingomonas sp, Sphingomonas suberifaciens, Sphingomonas trueperi, Sphingomonas wittichii, Sphingomonas xenophaga, Sphingomonas ya-buuchiae, Sphingomonas yunnanensis, et Sphingomonas yanoikuyae.In one embodiment of the invention, the bacterium is Sphingomonas xenophaga. In a preferred embodiment, the bacterium is a Sphingomonas xenophaga registered under the Treaty. from Budapest, on November 21, 2019, to the National Collection of Microorganism Cultures ((CNCM), Paris, France) under number CNCM 1-5455 by L'Oréal, 101 Avenue Gustave Eiffel, 37390 Notre Dame d'Oé.

[0016] As used here, the term "prevent" or "prevention" refers to any action aimed at preventing the occurrence of a disorder or one or more symptoms related to that disorder. This term therefore covers the slowing down, stopping, or limiting of symptoms.

[0017] As used herein, the term "treat" or "treatment" refers to any action aimed at suppressing, alleviating, or preventing the progression of a disorder or one or more symptoms related to that disorder. This term therefore encompasses the attenuation, relief, or suppression of symptoms.

[0018] “Prevention and / or treatment of skin reactions caused by an allergic reaction” means the slowing down, stopping, limiting, attenuating, relieving, or suppressing of skin symptoms caused by an allergic reaction in a subject. These symptoms generally include hives, a skin rash, and / or the appearance of redness.

[0019] The term "subject" here refers to a human being, preferably a human being suffering from allergies. In one embodiment of the invention, the subject has already experienced allergic reactions that have caused skin reactions.

[0020] By "cutaneous," we mean reactions to the skin, and more particularly to the area of ​​skin exposed or likely to be exposed to an allergen. According to one embodiment of the invention, cutaneous reactions caused by an allergic reaction include urticaria, a skin rash, and / or the appearance of redness.

[0021] In a preferred embodiment, the extracts and compositions used in the context of the invention are used topically. In a preferred embodiment, the extracts and compositions used in the context of the invention are intended for application to the skin.

[0022] In the context of the invention, the term "skin" refers to any cutaneous surface of the body, preferably the skin of the face, the skin of the neck, the décolleté, and more particularly the skin of the face.

[0023] By "allergic reaction," we mean the meaning commonly used by those skilled in the art, i.e., an exaggerated inflammatory reaction that occurs following exposure of the body to an allergen. This reaction is a sign of hypersensitivity of the body to substances, generally harmless and present in the environment: allergens. These substances can be found in the air, cosmetics, etc.

[0024] An immediate allergic reaction is characterized by the onset of symptoms most often a few minutes (less than two hours) after contact with the allergen. In this case, it is urticaria, which can become generalized and involves IgE. A delayed allergic reaction is characterized by the onset of symptoms generally 48 hours after contact with the allergen. In this case, it is eczema localized to the site of contact, involving chemical molecules.

[0025] In a preferred embodiment, the extracts and compositions implemented within the framework of the invention are used in the prevention and / or treatment of skin reactions caused by an immediate allergic reaction.

[0026] “Modulation of the immune response” herein means the slowing down, cessation, limitation, or attenuation of the immune response. In particular, modulation of the immune response according to the invention is a decrease in the activity of pro-inflammatory cytokines and / or an increase in the activity of anti-inflammatory cytokines.

[0027] In a preferred embodiment of the invention, the modulation of the immune response is achieved by increasing the activity of IL-10 without significantly impacting the pro-inflammatory interleukins IL-12, IL-6 and / or IL-8.

[0028] By "strengthening the skin barrier function", we mean here improving the skin barrier function, and in particular by increasing the number of tight junctions and / or by increasing associated proteins such as Claudin-1, Cornifelin and / or Zonula Occludens 1 at the skin level.

[0029] Extract of bacteria of the genus Sphingomonas

[0030] The present invention relates to an extract of bacteria of the genus Sphingomonas for its use in the prevention and / or treatment of skin reactions caused by an allergic reaction.

[0031] In the context of the invention, the term "bacterial extract" refers both to a set of compounds produced and / or secreted by a bacterium, therefore present in the culture medium of the bacterial culture (also called extracellular medium), and / or to a set of compounds included in the bacterium, therefore present in the bacterial pellet of the bacterial culture after centrifugation, such as the intracellular medium and / or the constituents of the cell walls and / or cell membranes.

[0032] The extracts according to the invention can be prepared by any conventional method well known to those skilled in the art. These methods typically include a fermentation, separation, and purification step.

[0033] Typically, the bacterium of the genus Sphingomonas is cultured in a suitable medium and grown to a desired density. Preferably, the bacteria themselves are concentrated by any known method, such as centrifugation. The concentrated bacteria can then be used directly as a crude preparation, or further processing steps well known to those skilled in the art may be carried out. processes such as freeze-drying, dehydration, filtration, purification, freezing possibly followed by thawing, sterilization, column chromatography, grinding, lysis, etc. may be carried out.

[0034] Preferably, the bacterial extract is a bacterial lysate. Such a lysate includes, in particular, the compounds contained within the bacterium, and therefore present in the bacterial pellet of the bacterial culture after centrifugation. Preferably, the bacterial extract is a bacterial lysate comprising the intracellular medium and / or the constituents of the cell walls and / or membranes.

[0035] A lysate commonly refers to a material obtained as a result of the destruction or dissolution of biological cells by a phenomenon known as cell lysis, thus causing the release of intracellular biological constituents naturally contained in the cells of the microorganism in question.

[0036] For the purposes of the present invention, the term lysate is used interchangeably to designate the entire lysate obtained by lysis of the microorganism concerned or only a fraction thereof.

[0037] The lysate used is therefore formed in whole or in part from intracellular biological constituents and from constituents of cell walls and membranes.

[0038] Preferably, the lysate used is therefore essentially formed in whole or in part from intracellular biological constituents and from constituents of cell walls and membranes.

[0039] In a preferred embodiment, the lysate comprises less than 1% by dry weight of extracellular medium, even better the lysate comprises between 0.5% and 1% by dry weight of extracellular medium, even more preferably the lysate comprises between 0.7% and 0.8% by dry weight of extracellular medium.

[0040] This cell lysis can be achieved by various technologies, such as osmotic shock, thermal shock such as freezing possibly followed by thawing, ultrasound, high pressure treatment or even under mechanical stress such as centrifugation for example.

[0041] Preferably, the lysate used in the context of the present invention is obtained by a process comprising the following steps:

[0042] i) a centrifugation step;

[0043] ii) a pellet recovery step;

[0044] iii) a step of freezing the pellet;

[0045] iv) a step of defrosting the pellet;

[0046] v) optionally a sterilization step by autoclaving, in particular at 121°C.

[0047] In a particular embodiment of the invention, the bacterial extract comprises an inactivated bacterium.

[0048] By "inactivated" is meant the meaning commonly used by those skilled in the art i.e., the suppression of bacterial activity under the effect of various causes (heat, chemical substances, mechanical, enzymatic). In particular, the bacterium is inactivated by heat, especially by autoclaving.

[0049] Said extract according to the invention preferably has an activity of activating hTLR2 receptors and / or promoting the expression of genes related to strengthening the skin barrier function.

[0050] Said extract preferably has an activity of inhibiting the secretion of the pro-inflammatory mediator PGE2.

[0051] Said extract preferably has an activity stimulating the expression of IL-10 without significantly impacting the expression of IL-12, IL-6 and IL-8.

[0052] Said extract preferably has an activity of inhibiting the production of IgE by B lymphocytes.

[0053] All these activities can be detected and / or analyzed by techniques known to a person skilled in the art, specific examples of which are described in the examples below.

[0054] Thus, bacteria of the genus Sphingomonas and their extracts have several anti-inflammatory activities combined with a strengthening of the skin barrier function allowing the prevention and / or treatment of skin reactions caused by allergic reaction.

[0055] The present invention also relates to a bacterial extract according to the invention for its use in modulating the immune response and optionally in strengthening the skin barrier function.

[0056] Composition

[0057] The present invention also relates to a composition, in particular intended for topical application, comprising an extract of bacteria of the genus Sphingomonas, or at least one bacterium of the genus Sphingomonas for its use in the prevention and / or treatment of skin reactions caused by allergic reaction.

[0058] The present invention also relates to a composition, comprising an extract of bacteria of the genus Sphingomonas, or at least one bacterium of the genus Sphingomonas for its use in modulating the immune response and optionally in strengthening the skin barrier function.

[0059] In one embodiment the composition comprises an extract as described above.

[0060] In one embodiment the composition comprises at least one bacterium of the genus Sphingomonas as described in the general definitions section.

[0061] The quantity of bacteria or bacterial extract in the composition according to the invention varies depending on the type of composition considered. Preferably, the quantity of microorganism or extract is between 0.0001 and 30% by dry weight relative to to the total weight of the composition, between 0.001 and 15% by dry weight relative to the total weight of the composition, between 0.01 and 10% by dry weight relative to the total weight of the composition, preferably between 0.01 and 5% by dry weight relative to the total weight of the composition, or between 0.01 and 3% by dry weight relative to the total weight of the composition.

[0062] In the case where the bacteria are formulated in a composition in a living form, the quantity of live bacteria can vary from 103 to 1015 ufc / g, in particular from 105 to 1015 ufc / g and more particularly from 107 to 1012 ufc / g of bacteria per gram of composition.

[0063] The composition according to the invention preferably comprises an aqueous phase.

[0064] Preferably, the composition according to the invention has a water content ranging from 20% to 95% by weight, and preferably from 30% to 70% by weight relative to the total weight of the composition.

[0065] The composition according to the invention may further comprise one or more water-miscible organic solvents in a content ranging from 0.5% to 25% by weight, preferably from 5% to 20% by weight, even better from 10% to 15% by weight relative to the total weight of the composition.

[0066] As previously stated, the compositions used within the framework of the invention are preferably used topically.

[0067] As is well known to those skilled in the art, topical compositions may also contain common excipients, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active ingredients other than the extract according to the invention, preservatives, antioxidants, water-immiscible solvents, perfumes, odor-absorbing agents, and colorants. The quantities of these various excipients are those typically used in this particular field, and range, for example, from 0.01% to 20% of the total weight of the composition.

[0068] Of course, a person skilled in the art will take care to choose this or these possible complementary ingredients and / or active ingredients, and / or their quantity, in such a way that the advantageous properties of the extract according to the invention are not, or substantially not, altered by the envisaged addition.

[0069] In one embodiment, bacteria of the genus Sphingomonas or an extract of bacteria of the genus Sphingomonas is the only active agent in the composition.

[0070] In another embodiment, the composition of the invention may further contain other active agents different from the bacteria or extract according to the invention. These active agents may have an effect on the skin and in particular a soothing effect.

[0071] In a particular embodiment of the invention, the composition according to the invention further comprises at least one active agent selected from acetyl dipeptide-1 cetyl ester, a root extract of Salvia miltiorrhiza, a thermal water such as water of La Roche Posay, and their blends.

[0072] The compositions according to the invention can be presented in all the pharmaceutical forms conventionally used for topical application, and in particular in the form of aqueous solutions, hydroalcoholic solutions, oil-in-water (O / W) or water-in-oil (W / O) emulsions or multiple emulsions (triple: W / O / W or W / O / O), aqueous gels, or dispersions of an oily phase in an aqueous phase using spherules, these spherules being lipid vesicles of ionic and / or non-ionic type (liposomes, niosomes, oleosomes). These compositions are prepared according to conventional methods.

[0073] Advantageously, the compositions according to the invention are in the form of a gel, an emulsion, or a paste. Furthermore, the composition according to the invention may be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foaming or non-foaming gel, a scrub, a mask, a treatment, a toner, or a mousse. It may optionally be applied to the skin in the form of an aerosol. It may also be in solid form, for example, as a stick or a soap.

[0074] A composition according to the invention may include a fatty phase, in particular an oily phase.

[0075] Examples of oils that can be used in the composition of the invention include:

[0076] - hydrocarbon oils,

[0077] - synthetic esters and ethers, particularly of fatty acids, such as oils of formulas R'COOR2 and R'COR2 in which R' represents the remainder of a fatty acid containing 8 to 29 carbon atoms, and R2 represents a hydrocarbon chain, branched or unbranched, containing 3 to 30 carbon atoms;

[0078] - linear or branched hydrocarbons, of mineral or synthetic origin;

[0079] - fatty alcohols having from 8 to 26 carbon atoms;

[0080] - partially hydrocarbon and / or silicone fluorinated oils;

[0081] - silicone oils;

[0082] - their mixtures.

[0083] In the list of oils cited above, hydrocarbon oil means any oil consisting mainly of carbon and hydrogen atoms.

[0084] The oil phase may contain other fatty substances that may be present in the oil phase, such as fatty acids with 8 to 30 carbon atoms; waxes; silicone resins; and silicone elastomers. These fatty substances can be chosen in a variety of ways by those skilled in the art to prepare a composition having the desired properties, for example, of consistency or texture.

[0085] According to a particular embodiment of the invention, the composition according to the invention is a water-in-oil (W / O) or oil-in-water (O / W) emulsion. The proportion of the oil phase in the emulsion can range from 5 to 80% by weight, and preferably from 30 to 70% by weight relative to the total weight of the composition. Emulsions generally contain at least one emulsifier chosen from amphoteric, anionic, cationic, or nonionic emulsifiers, used alone or in mixtures, and possibly a co-emulsifier. Emulsifiers are chosen appropriately depending on the emulsion to be obtained (oil-in-oil or water-in-water). The emulsifier and co-emulsifier are generally present in the composition, in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.

[0086] For W / O emulsions, dimethicone copolyols and alkyl-dimethicone copolyols can be cited as examples of emulsifiers. A crosslinked solid organopolysiloxane elastomer comprising at least one oxyalkylated group can also be used as a surfactant in W / O emulsions.

[0087] For O / W emulsions, non-ionic emulsifiers can be cited as examples.

[0088] The composition may or may not be rinsed off after being applied to the skin.

[0089] Processes

[0090] The present invention also relates to a method for preventing or treating skin reactions caused by an allergic reaction comprising administering, preferably topically to the surface of the skin, an extract of bacteria of the genus Sphingomonas or a composition comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas.

[0091] The use of an extract of bacteria of the genus Sphingomonas or of a composition comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas in the manufacture of a medicinal product for the prevention or treatment of skin reactions caused by an allergic reaction is also proposed.

[0092] The present invention also relates to a method of modulating the immune response and optionally strengthening the skin barrier function, comprising administering, preferably topically to the skin surface, an extract of bacteria of the genus Sphingomonas or a composition comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas.

[0093] The use of an extract of bacteria of the genus Sphingomonas or of a composition comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas in the manufacture of a drug for the modulation of the immune response and optionally the strengthening of the skin barrier function, is also proposed.

[0094] In a particular embodiment, the composition comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas is as described in the composition section above.

[0095] In a particular embodiment, the extract of bacteria of the genus Sphingomonas is as described in the section on extract of bacteria of the genus Sphingomonas above.

[0096] Preferably the application is carried out on a subject who needs it and in an effective quantity of at least one extract of bacteria of the genus Sphingomonas or at least one composition comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas.

[0097] As used herein, the term "effective amount" refers to the amount of Sphingomonas bacteria extract which, as a whole, prevents and / or reduces skin reactions caused by an allergic reaction, or to the amount of Sphingomonas bacteria which, as a whole, prevents and / or reduces skin reactions caused by an allergic reaction.

[0098] The effective quantity naturally depends on the active ingredient in question, the method of administration, the therapeutic indication, the age of the patient and his condition.

[0099] Advantageously, the composition or extract is in particular used in the form of a dermatological composition, possibly further comprising a physiologically acceptable excipient.

[0100] By "physiologically acceptable" is meant compositions and molecular entities that do not produce adverse, allergic, or otherwise undesirable reactions when administered to a subject. A physiologically acceptable excipient or vehicle is thus an encapsulating material, a diluent, a support, or any other non-toxic liquid, semi-solid, or solid formulation aid.

[0101] The dermatological compositions used in the context of the invention are typically prepared to suit the method of administration. The physiologically acceptable excipients are typically determined in part by the composition administered, as well as by the particular technique used to administer the composition.

[0102] The dosage of compounds to be administered depends on the individual case and, as is well known to those skilled in the art, must be adapted to the individual circumstances to obtain an effective quantity and optimum effect. The effective dose level is specific to each subject and will depend in particular on a variety of factors, including the disorder being treated and the severity of the disorder, the activity of the specific compound used, and the specific composition employed. For example, it is well known to those skilled in the art to start with doses of the compound at levels lower than those required to achieve the desired effect and to gradually increase the dose until the desired effect is obtained.

[0103] Preferably the methods according to the invention include the topical application of at least one bacterium of the genus Sphingomonas or at least one extract of the genus Sphingomonas or of a composition therein or comprising it.

[0104] In a preferred embodiment, topical application within the framework of the invention is application to the skin.

[0105] The methods of the invention may include a single administration. In another embodiment, the administration is repeated, for example, 2 to 3 times a day for one or more days, or a daily application for several consecutive or non-consecutive days, and generally for a prolonged period of at least 4 weeks or 4 to 15 weeks, or as long as necessary with a possible break if needed.

[0106] In another embodiment, the methods of the invention may include administration to an area of ​​the skin before and / or after exposure of that area to an allergen.

[0107] In the description and the following examples, unless otherwise stated, percentages are percentages by weight and ranges of values ​​written as "between ... and..." include the specified upper and lower limits. The ingredients are mixed, before shaping, in the order and under conditions readily determined by a person skilled in the art.

[0108] The present invention will be further illustrated by the examples below. Figure:

[0109] [Fig-1] Fig. 1 represents the effect of Sphingomonas extract on the secretion of cytokines by monocytes. Examples

[0110] Example 1: Preparation of an extract according to the invention

[0111] A culture of the Sphingomonas xenophaga CNCM-I 5455 strain is carried out in its complete culture medium in a bioreactor of 3000 liters effective in batch mode. During this stage, the pH is not regulated, the temperature is maintained at 26 °C and the dissolved oxygen at 30%.

[0112] The composition of the initial culture medium is described in Table 1 below.

[0113] [Tables 1] Chemical name concentration Autolytic yeast extract 4 g / L Soybean peptone F 3 g / L Glucose 3 g / L KH2PO4 0.088 g / L CaCl2 0.050 g / L CuSO4, 5 H2O 60 pg / L MnSO4, 1H2O 152 pg / L Kl 20 pg / L ZnSO4, 7H2O 200 pg / L AlCl3, 6H2O 100 pg / L Osmosis water qsp 1 1

[0114] Once the plateau phase is reached, cell extraction and separation are carried out by centrifugation (10,000 g continuous). The pellet, also called biomass, containing the cells is then collected, frozen at -20°C, and subsequently thawed, allowing the cells to rupture and thus yielding a lysate. The lysate is then packaged in bags and finally stabilized by sterilization at 121°C for 30 minutes.

[0115] The lysate obtained at the end of the process as described in example 1 contains 4.5% by weight of dry matter, relative to the total weight of the lysate.

[0116] Example 2: In vitro test - dose-response analysis of TLRs (Invivogen).

[0117] HEK293-TLR cell lines:

[0118] The extract and controls are tested in duplicates on recombinant HEK-293 cell lines. These cell lines functionally overexpress human TLR proteins as well as a reporter gene that is a secreted alkaline phosphatase (SEAP). Production of this reporter gene is directed by an inducible NF-κB promoter. The TLR reporter activation results are given as optical density (OD) values.

[0119] Positive tests:

[0120] CU-T12-9 and FSL-1 are used on cells expressing hTLR2 to evaluate res respectively the activities TLR1 / TLR2 and TLR2 / TLR6.

[0121] FSL-1 is tested at 10 pg / ml and 30 pg / ml. CU-T12-9 is tested at 200nM and 300nM.

[0122] Negative checks:

[0123] A recombinant HEK-293 cell line for the reporter gene only was used as a negative control for cell lines expressing hTLR. To validate the efficacy of the inducible reporter gene NFkB (SEAP), this HEK-293 TLR cell line was stimulated with TNFα at the following concentrations: 100 ng / ml, 30 ng / ml, 10 ng / ml, 3 ng / ml, 1 ng / ml, 0.3 ng / ml, and 0.1 ng / ml.

[0124] This negative control cell line was also stimulated with different concentrations of the tested extract.

[0125] Extract test:

[0126] 20 µl of the extract were used to stimulate reporter cell lines hTLR in 200 µl reaction volume. For dose-response on HEK-Blue-hTLR5 cell lines, the liquid extract obtained according to Example 1 was tested in duplicate, at the following concentrations: 1000 pg / ml, 500 pg / ml, 250 pg / ml, 125 pg / ml, 62.5 pg / ml, 31.5 pg / ml.

[0127] For TLR1 / 2 and / or TLR2 / 6 specificity, the liquid extract obtained according to Example 1 was tested in duplicate at the following concentrations: 100 pg / ml, 30 pg / ml and 10 pg / ml. Results:

[0128] [Table 2] Results on the cell line with hTLR2 Tested compound - concentration DO CUT12-9 300 nM 3.227 Cutl2-9 200 nM 3.066 FSL1 30 pg / ml 2.174 FSL1 10 pg / ml 1.727 Liquid extract obtained according to example 1 100 pg / ml 3.890 Liquid extract obtained according to example 1 30 pg / ml 3.867 Liquid extract obtained according to example 1 10 pg / ml 3.381

[0129] [Table 3] Results on the cell line with hTLR2-l Tested compound - concentration DO CUT12-9 300 nM 1.667 Cutl2-9 200 nM 1.474 FSL1 30 pg / ml 0.013 FSL1 10 pg / ml 0.027 Liquid extract obtained according to example 1 100 pg / ml 3.246 Liquid extract obtained according to example 1 30 pg / mL 2.755 Liquid extract obtained according to example 1 10 pg / mL 1.613

[0130] [Table 4] Results on the cell line with hTLR2-6 Tested compound - concentration DO CUT12-9 300 nM 0.024 Cutl2-9 200 nM 0.029 FSL1 30 pg / ml 2.047 FSL1 10 pg / ml 1.373 Liquid extract obtained according to example 1 100 pg / ml 3.704 Liquid extract obtained according to example 1 30 pg / ml 3.463 Liquid extract obtained according to example 1 10 pg / ml 2.233 Conclusion :

[0131] The extract does not activate the negative control cell line but strongly activates the hTLR2 (1 / 6) reporter cell line, even at 10 pg / ml. It non-specifically activates hTLR1 / 2 and hTLR2 / 6.

[0132] Example 3: In vitro test - Modulation of gene expression in normal human keratinocytes Materials and methods

[0133] Cytotoxicity:

[0134] Normal human epidermal keratinocytes were seeded in 96-well culture plates and then cultured at 37 °C and 5% CO2 in culture medium for 24 hours. The medium was then replaced with a culture medium containing or not (control) the compounds to be tested (8 concentrations tested), and the cells were then incubated for 24 hours. All conditions were performed in duplicate. At the end of incubation, cell viability was measured by a standard mitochondrial activity assay.

[0135] Analysis of the expression of genes associated with barrier / hydration function by RT- qPCT:

[0136] Normal human epidermal keratinocytes (NHEK) were seeded in 48-well culture plates and then cultured in culture medium for 3 days at 37 °C and 5% CO2, with the culture medium being changed after the first 24 hours of culture. At the end of the incubation period, the culture medium was replaced with test medium (supplemented with 1.5 mM CaCl2) either containing no (control) or containing the compounds to be tested, and the cells were then incubated for 24 hours. All conditions were performed in duplicate.

[0137] At the end of the treatments, the culture media were removed and the cells were rinsed twice with PBS (without CaCl2, without MgCl2). Total RNA was then isolated using an extraction kit. RNA quantification and quality control were analyzed using Labchip GX (Perkin Elmer).

[0138] The expression of the selected transcripts was analyzed by quantitative PCR in two steps. First, the cDNAs were reverse-transcribed from the RNAs. The quantitative PCR experiments were then performed using a real-time PCR system.

[0139] Experimental protocol

[0140] Normal human epidermal keratinocytes are cultured and amplified to produce enough cells to evaluate up to 72 samples per campaign. 48-well microplates are seeded with the cells (50,000 cells per well) and incubated for 48 hours in a temperature-, humidity-, and CO2-controlled environment. The samples to be tested are added to the cells during a replenishment of the culture medium, and the cells are then incubated for 24 hours.

[0141] The cells are washed and dry-frozen at -80°C to preserve the RNA. The RNAs are extracted, quantified, and their quality is checked before reverse transcription into cDNA. RT-qPCR is then performed for each experimental condition to quantify the expression of the selected gene set.

[0142] [Table 5] Results Average gene expression of Sphingomonas Retinol Lyophilized liquid extract obtained according to example 1 0.2 1 l,00E-07 g / L g / LM Gene group WATER WATER DMSO Barrier function Claudin 1 2.51 2.51 0.63 Cornifelin 9.66 19.43 0.77 Zonula Occludens-1 3.81 3.87 1.61

[0143] The batch of Sphingomonas tested in this example corresponds to the lyophilized (100% DM) of the liquid extract obtained according to example 1 (4.5% DM).

[0144] Taking into account that Ig / L corresponds to a concentration of 0.1%, in conclusion, the liquid extract obtained according to Example 1 allows a significant modulation of expression in NHEK at 0.0009% (calculation: 0.2 x 0.1 x 0.045) and at 0.0045% (calculation: 1 x 0.1 x 0.045) on the Claudine-1, Cornifelin and Zonula Occludens 1 genes.

[0145] Example 4: In vitro test “evaluation of the regulation of PGE2 release by human myeloid cells”

[0146] Anti-inflammatory efficacy test on the human myeloid cell line U937 (sourced from Dr. Kenneth NILSSON, Professor of Cellular Pathology in the Department of Immunology, Genetics and Pathology at Uppsala University, Rap-phonsvagen 11, 75653 Uppsala, Sweden).

[0147] Test principle

[0148] The cell line is used in this protocol to model the immune response of monocytes / macrophages in vitro. Treatment with PMA and LPS induces the secretion of pro-inflammatory mediators and cytokines. Co-treatment with anti-inflammatory agents allows the identification of the intrinsic regulatory activity of the pro-inflammatory reaction in vitro.

[0149] Cellular treatment

[0150] The human myeloid cell line was treated with Sphingomonas xenophaga extract in RPMI 1640 culture medium supplemented with L-glutamine, penicillin, streptomycin, 10% heat-treated fetal bovine serum, 10 pg / mL of Phorbol 12-myristate 13-acetate (PMA), and 60 pg / mL of lipopolysaccharides for E. coli (LPS). Seven concentrations of Sphingomonas xenophaga extract were tested: 1, 3, 10, 30, 100, 300, and 1000 pg / mL.

[0151] Twenty-four hours after treatment at 37°C in a humidified atmosphere with 5% CO2, cell viability was measured for each condition.

[0152] The supernatants were then collected for the determination of PGE2.

[0153] Cytokine assay

[0154] PGE2 levels are determined by ELIS A test. Viability calculation - CV75

[0155] CV75 = Cl + ((VI - 75) / (VI - V2)) x (C2-C1)

[0156] Where

[0157] Cl = lowest concentration with viability >75%

[0158] C2 = highest concentration with viability <75%

[0159] VI = lowest viability percentage > 75%

[0160] V2 = highest viability percentage <75% Calculation of the Reactivity Index (RI)

[0161] RI = quantity of marker (pg / ml) of treated supernatants x 100 / quantity of analytes (pg / ml) in untreated supernatants.

[0162] Calculation of the 50% inhibitory concentration - IC50

[0163] IC50 = Cl + ((50 - RII) / (RI2 - RII)) x (C2 - Cl)

[0164] Where

[0165] Cl = highest concentration with RI <50

[0166] C2 = lowest concentration with RI > 50

[0167] RII = highest RI <50

[0168] RI2 = lowest RI > 50

[0169] [Table 6] Results Extract dose in pg / ml Viability in % RI of PGE2 expressed as % relative to the control (solvent) 1 101 102 3 102 88 10 101 92 30 103 91 100 103 72 300 101 28 1000 93 0.1

[0170] Sphingomonas extract inhibits the secretion of the pro-inflammatory mediator with an IC50 of 199 pg / ml.

[0171] Example 5: In vitro test of the effect of the extract on the secretion of cytokines (IL-6, IL-8, IL-10 and IL-12p40) by monocytes.

[0172] The objective of the trial is to study the effects of the extract on cytokine secretion by monocytes after 36h.

[0173] Materials and methods:

[0174] Cell isolation and culture:

[0175] Mononuclear cells were obtained from leukocyte layers of healthy blood donors using a standard Ficoll-Hypaque gradient method. Monocytes were isolated from the mononuclear cells by adhesion to plastic for 2 hours in serum-free medium (SFM) optimized for macrophage culture, at 37°C in a humidified atmosphere containing 5% CO2. The adherent cells, highly enriched in monocytes, were incubated with test compounds for 36 hours.

[0176] Cytotoxicity test:

[0177] During the last 6 hours, Alamar Blue was introduced into the cell culture. Resorufin, a fluorescent molecule obtained by conversion of one of the components of Alamar Blue, was measured as an indicator of cell death. The measurement was performed using the Tecan Infinité F500 spectrofluorimeter.

[0178] Cytokine assay:

[0179] After 36 h, the supernatants are collected and frozen at -80°C until analysis. The measurement was performed using the Milliplex assay kit (IL-6; IL-8; IL-10 and IL-12p40) on the Luminex LX100 instrument.

[0180] Calculation method for evaluating results:

[0181] Since the ranges of values ​​are different between cytokines and in order to obtain a value that is easy to compare between compounds, the multiplication factor is different depending on the cytokine compared to IL-10.

[0182] Comparison between IL-10 and IL-6: the ratio is IL-10 x 100 / IL-6

[0183] Comparison between IL-10 and IL-12p40: the ratio is IL-10 / IL-12p40

[0184] Comparison between IL-10 and IL-8: the ratio is IL-10 x 100,000 / IL-8

[0185] The results are shown in [Fig. 1]. Product 2 corresponds to the extract liquid obtained according to Example 1.

[0186] The extract has immunoregulatory effects on monocytes: IL10>IL-6 / IL-8 / IL-12(p40).

[0187] The extract induces a strong dose-effect production of IL-10 (anti-inflammatory cytokine) compared with IL-6 and IL-8 (pro-inflammatory cytokines).

[0188] Example 6: In vitro test of the effect of the extract on IgE production by human B lymphocytes stimulated with the combination of anti-CD40 and IL-4

[0189] In the study, the effect of the extract was evaluated on IgE production by purified human B lymphocytes (CD19+ lymphocytes isolated from peripheral blood mononuclear cells). More specifically, IgE production was induced by stimulating B lymphocytes with a combination of an anti-CD40 antibody and IL-4. After 14 days of incubation, the amount of IgE released into the culture supernatants was quantified using a specific ELISA kit. In parallel with the tested extract, three other molecules were also evaluated in this test: the standard reference compounds CpG-ODN 2006 (TLR9 ​​ligand), as well as IFN-y and PGE2 which were tested as reference compounds.

[0190] [Table 7] Compounds studied Tested Compound Appearance / Storage Stock Solution Tested Concentrations Extract from Example 1 (lysate) - opaque liquid - Storage: +4°C protected from moisture The 4.6% liquid in water is considered a 100% stock solution 0.2% and 0.4% Reference Compounds Appearance / Storage Stock Solution Tested Concentrations CpG-ODN 2006 Invivogen, ref. tlrl-2006 - Powder - Storage: -20°C 500 pM in ultrapure water 3 pM IFN-y R&D Systems, ref. 285-IF-100 / CF - Powder - Storage: -80°C 200 pg / ml in ultrapure water 10 ng / ml pge2 Sigma, ref. P0409 - Powder - Storage: -20°C 2.837 mM in ethanol 1 pM

[0191] Culture and processing

[0192] CD19+ B lymphocytes were isolated, seeded in 24-well plates, and incubated overnight in culture medium. The test compounds, alone or in combination, and the reference compounds were then added or not (controls), and the cells were pre-incubated for 2 hours. The inducer (CD40 + IL-4 combination) was then added or not (unstimulated control), and the treatments with the test or reference compounds were repeated. The cells were then incubated for 14 days to a final density of 1.7 x 10⁶ cells / ml.

[0193] All experimental conditions were carried out in n = 3.

[0194] Enzyme-linked immunosorbent assay (ELISA)

[0195] The amount of IgE released into the culture supernatants was measured using a specific ELISA kit according to the supplier's instructions.

[0196] Statistics

[0197] Inter-group comparisons were performed using an unpaired Student's t-test. The statistical analysis can be interpreted if n > 5, however for n < 5 the Statistical values ​​are given for informational purposes only.

[0198] Formulas used in this report:

[0199] Standard error of the mean:

[0200] SEM = Sd / Vn

[0201] The standard error of the mean (SEM) is a measure of the difference between the sample mean and the true population mean. The SEM is calculated as the sample standard deviation (Sd) divided by the square root of the sample size (n).

[0202] Results and conclusion

[0203] Under unstimulated conditions, the baseline level of IgE release by B lymphocytes is very low (<199 pg / ml, close to the limit of detection). Stimulation for 14 days with the anti-CD40 + IL-4 combination resulted in a high level of IgE production (3657 pg / ml). The TLR9 agonist CpG-ODN2006, tested as a reference compound at 3 pM, completely inhibited IgE production induced by the anti-CD40 + IL-4 combination (<3% of the stimulated control). These results were expected and validated the test.

[0204] The two other potential reference compounds also showed an inhibitory effect on IgE production, but to a lesser extent than CpG-ODN2006. IFN-γ, tested at 10 ng / ml, again showed a fairly strong and significant inhibitory effect (20% of the stimulated control). However, the effect of PGE2, tested at 1 pM, was much more limited and statistically insignificant (58% of the stimulated control).

[0205] The extract from Example 1, tested at 0.2% and 0.4%, showed an almost complete inhibitory effect on IgE production by B lymphocytes stimulated by the antiCD40 + IL-4 combination (<3% and <11% of the stimulated control, respectively).

[0206] Under the experimental conditions of this study, the different concentrations of the extract from Example 1 showed a very powerful inhibitory effect on the production of IgE by B cells stimulated by the anti-CD40 + IL-4 association.

[0207] [Table 8] Summary of results Tested compound and mean IgE concentration (pg / ml) SEM (pg / ml) % of stimulated control SEM % P Unstimulated control - 349 <123 <123 <199 75 <5 2 ** Anti-CD40 10 pg / ml + IL-4 10 ng / ml Control 3076 4924 2970 3657 634 100 17 * CpG-ODN 2006 3 pM <123 <123 <123 <123 0 <3 0 ** IFN-γ 10 ng / ml 1012 166 1036 738 286 20 8 * pge2 IpM 2942 1495 1941 2126 428 58 12 ns Sphingomonas extract from example 1 (lysate) 0.2% <123 <123 <123 <123 0 <3 0 ** Sphingomonas extract from example 1 (lysate) 0.4% <123 <123 958 <402 278 <11 8 **

[0208] ns: >0.5 not significant

[0209] *: 0.01 to 0.05 significant

[0210] ** : 0.001 to 0.01, very significant

[0211] < or > : less than or greater than the detection limit

[0212] <123,457 or >90,000 pg / ml for undiluted samples

[0213] In the case of a value lower or higher than the detection limits, the following calculations are extrapolated. Example 7

[0214] A gel with the following composition was prepared:

[0215] [Table 9] Composition of the gel Compounds Quantity (in g) Lyophilized liquid extract obtained according to example 1 1 g Xanthan gum 0.5 g Preservatives qs Water qsp 100 g

[0216] The resulting composition was applied to the face of allergic-prone skin.

Claims

Claims

1. Extract of bacteria of the genus Sphingomonas xenophaga for use in the prevention and / or treatment of skin reactions caused by an allergic reaction, said bacteria extract being a bacteria lysate.

2. Composition comprising an extract of bacteria of the genus Sphingomonas xenophaga or at least one bacterium of the genus Sphingomonas xenophaga for use in the prevention and / or treatment of skin reactions caused by allergic reaction, said bacteria extract being a bacteria lysate.

3. Extract for its use according to claim 1 or composition for its use according to claim 2, in which the bacterium of the species Sphingomonas xenophaga is of the strain deposited under accession number CNCM 1-5455.

4. Extract for its use according to claim 1 or 3, or composition for its use according to claim 2 or 3, for its use topically, preferably on the surface of the skin.

5. Composition for use according to any one of claims 2 to 4, wherein the concentration of the extract is between 0.0001% and 30% by weight relative to the total weight of the composition.

6. Composition for its use according to one of claims 2 to 5, further comprising at least one active agent selected from the group consisting of acetyl dipeptide-1 cetyl ester, an extract of S al via miltiorrhiza root, a thermal water such as La Roche Posay water and mixtures thereof.

7. Extract for use according to any one of claims 1 or 3 to 4 or composition for use according to any one of claims 2 to 6, wherein the allergic reaction is an immediate type allergic reaction.

8. An extract for use according to any one of claims 1, 3, 4 or 7, or a composition for use according to any one of claims 2 to 7, wherein the reaction comprises hives, a rash and / or the appearance of redness.

9. Extract of bacteria of the genus Sphingomonas xenophaga for its use in modulating the immune response and optionally in strengthening the barrier function of the skin, said bacteria extract being a lysate of bacteria.

10. Composition comprising an extract of bacteria of the genus Sphingomonas xenophaga or at least one bacterium of the genus Sphingomonas, for use in modulating the immune response and optionally strengthening the barrier function of the skin, said bacteria extract being a bacteria lysate.